Simple Summary Immune checkpoint inhibitors (ICIs) are the most mature treatment of
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …

Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Background The antitumor efficacy of immune checkpoint inhibitors (ICIs) has increasingly
emerged during the last few years. However, there is a need to identify the safety profile of …

Background Cancer immunotherapy shows unique efficacy kinetics that differs from
conventional treatment. These characteristics may lead to the prolongation of trial duration …

B7x (also called B7-H4) is a co-inhibitory molecule of B7 family that is highly expressed in
non-inflamed or cold cancers, and its aberrant expression is contributed to cancer …

Introduction Triple-negative breast cancer (TNBC) is a highly aggressive subtype with a poor
prognosis. Current single-agent checkpoint therapy has limited effectiveness in TNBC …

Hepatocellular carcinoma (HCC) has one of the highest mortality rates among solid cancers.
Late diagnosis and a lack of efficacious treatment options contribute to the dismal prognosis …

Optimizing neoadjuvant therapy for triple‐negative breast cancer (TNBC) is still an urgent
problem to be solved in the clinic. In this prospective cohort study, we investigated the …